Corvus Pharmaceuticals
CRVS
37 hedge funds and large institutions have $113M invested in Corvus Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 5 closing their positions.
64% more capital invested
Capital invested by funds: $68.9M → $113M (+$44.1M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
6% more funds holding
Funds holding: 35 → 37 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7.23% less ownership
Funds ownership: 77.89% → 70.66% (-7.2%)
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.58M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$468K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$277K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$238K |
| 5 |
Renaissance Technologies
New York
|
+$190K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.97M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.32M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.28M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$874K |
| 5 |
Millennium Management
New York
|
-$533K |
CRVS Hedge Fund Activity: Q4 2019 in Review
37 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2019, worth a combined $113M — up 64% from $68.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CRVS positions and 5 closed out — a net gain of 2 holders — while 8 added to existing stakes and 16 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $2.58M. The largest seller was BVF Inc, cutting an estimated $4.97M.
- 37 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2019, up from 35 in Q3 2019.
- Funds reported $113M of Corvus Pharmaceuticals stock for Q4 2019, up 64% quarter-over-quarter.
- 7 funds opened new Corvus Pharmaceuticals positions in Q4 2019 and 5 closed out, a net change of +2 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2019 was EcoR1 Capital, an estimated $2.58M added.
- The largest Corvus Pharmaceuticals seller in Q4 2019 was BVF Inc, an estimated $4.97M sold.
Based on aggregated 13F filings for Q4 2019.